Premium
Pharmacogenomics Implementation at the National Institutes of Health Clinical Center
Author(s) -
Sissung Tristan M.,
McKeeby Jon W.,
Patel Jharana,
Lertora Juan J.,
Kumar Parag,
Flegel Willy A.,
Adams Sharon D.,
Eckes Ellen J.,
Mickey Frank,
Plona Teri M.,
Mellott Stephanie D.,
Baugher Ryan N.,
Wu Xiaolin,
Soppet Daniel R.,
Barcus Mary E.,
Datta Vivekananda,
Pike Kristen M.,
DiPatrizio Gary,
Figg William D.,
Goldspiel Barry R.
Publication year - 2017
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.993
Subject(s) - pharmacogenomics , medicine , genotyping , pharmacogenetics , allopurinol , intensive care medicine , pharmacology , genetics , biology , genotype , gene
The National Institutes of Health Clinical Center (NIH CC) is the largest hospital in the United States devoted entirely to clinical research, with a highly diverse spectrum of patients. Patient safety and clinical quality are major goals of the hospital, and therapy is often complicated by multiple cotherapies and comorbidities. To this end, we implemented a pharmacogenomics program in 2 phases. In the first phase, we implemented genotyping for HLA‐A and HLA‐B gene variations with clinical decision support (CDS) for abacavir, carbamazepine, and allopurinol. In the second phase, we implemented genotyping for drug‐metabolizing enzymes and transporters: SLCO1B1 for CDS of simvastatin and TPMT for CDS of mercaptopurine, azathioprine, and thioguanine. The purpose of this review is to describe the implementation process, which involves clinical, laboratory, informatics, and policy decisions pertinent to the NIH CC.